Recent News

• 04.16.2025 - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
• 04.08.2025 - Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
• 04.03.2025 - Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
• 03.17.2025 - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
• 02.26.2025 - Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 8-K Current report
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities